According to Tetra’s Chief Executive Officer (CEO), Bernard Fortier,” Tetra is in a good position to penetrate this market. We have been preparing for months how to differentiate ourselves within this market while maintaining our corporate vision of an evidence-based approach. The cannabis oil market will be no different for Tetra.
Furthermore, Tetra is announcing that it is supporting a post-marketing study (phase 4 clinical trial) of the use of cannabis oil in the treatment of chronic pain. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population.